MK-677, also known as Ibutamoren, is technically not a peptide — it's a non-peptide small molecule that acts as a ghrelin receptor agonist. It's included here because it functions identically to injectable GH secretagogue peptides but with one major practical difference: it's orally bioavailable. You take it as a pill or liquid and it stimulates GH release without any injection. This makes it the most accessible GH secretagogue for people who want the benefits of GH optimisation without needles.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
MK-677 (Ibutamoren) is an orally active non-peptide ghrelin receptor agonist. It mimics ghrelin to stimulate the pituitary to release growth hormone. Unlike injectable GH secretagogue peptides, it survives oral administration intact, making it accessible without needles.
How Does MK-677 Work?
MK-677 acts on the ghrelin receptor (GHSR-1a) — the same receptor that Ipamorelin and other GHRPs target. By binding GHSR-1a, it mimics the ghrelin signal that triggers pulsatile GH release from the pituitary.
What makes MK-677 unique is its pharmacokinetics. Most peptides are broken down in the digestive tract before reaching systemic circulation, which is why GH secretagogue peptides require injection. MK-677's small molecule structure is stable through oral administration — it survives gastric acid and intestinal enzymes, reaches the bloodstream intact, and crosses the blood-brain barrier to act on hypothalamic GHSR receptors.
Half-life is approximately 24 hours, meaning once-daily oral dosing maintains consistent receptor activation. This produces a more sustained GH elevation pattern compared to the sharp pulses of injectable GH secretagogues — different from physiological pulsatility but convenient for long-term use.
Clinical Research: The Most Studied Secretagogue
MK-677 has undergone more human clinical research than most compounds in the GH secretagogue category. Eli Lilly and later Merck investigated it across multiple indications, generating a meaningful body of human data.
Key findings: A double-blind, randomised trial in elderly subjects (Sigalos and Pastuszak, 2018, reviewed the accumulated data) showed significant increases in IGF-1 and GH. Lean mass increased and fat mass decreased in several trials. Bone mineral density improvements were observed. Sleep quality improvements (particularly increased REM and slow-wave sleep) were consistently reported across trials.
The largest concern to emerge from human trials is insulin resistance. MK-677 elevates GH substantially, and GH antagonises insulin signalling. Chronic use has shown meaningful increases in fasting glucose and insulin levels. This is a real risk that distinguishes MK-677 from more selective secretagogues like Ipamorelin that produce more modest, pulsatile GH elevation.
What Is the Recommended MK-677 Dosage?
| Protocol | Dose | Timing | Notes |
|---|---|---|---|
| Conservative / beginner | 10 mg/day | Before sleep | Less water retention, lower GH elevation |
| Standard | 20 mg/day | Before sleep | Most common research dose |
| High dose | 25–30 mg/day | Before sleep | More side effects, higher IGF-1 |
| Bulking protocol | 20–25 mg/day | Before sleep | Often combined with CJC-1295 |
| Anti-aging / longevity | 10–15 mg/day | Before sleep | Lower dose for long-term use |
Side Effects: What to Know Before Starting
**Water retention** is the most common and usually the most noticeable effect, especially in the first 2–4 weeks. Puffiness in the face and extremities. Dose-dependent — 10 mg produces significantly less retention than 25 mg. Usually diminishes after the adaptation period.
**Increased appetite:** MK-677 activates ghrelin receptors, and ghrelin is a powerful appetite hormone. Hunger increases significantly, particularly in the evening. This can be advantageous for hard gainers or people trying to increase caloric intake, and problematic for anyone managing weight.
**Insulin resistance:** The most medically significant concern. MK-677 elevates GH, which increases free fatty acids and antagonises insulin signalling. Fasting glucose and insulin levels rise with chronic use. Monitoring blood glucose is advisable for anyone using MK-677 longer than 3 months, and people with pre-diabetes or metabolic syndrome should approach with particular caution.
**Lethargy / brain fog:** Some users experience reduced mental sharpness in the first few weeks. Usually resolves with the adaptation period.
**Sleep deepening:** Most users report improved sleep depth and increased dreaming, consistent with the enhanced slow-wave sleep GH pulse. Generally positive.
**Cycling:** Unlike injectable GH secretagogues, MK-677's 24-hour half-life makes cycling optional. Many long-term protocols use it continuously at 10–15 mg with periodic blood glucose monitoring.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
MK-677 (Ibutamoren) is an orally active non-peptide ghrelin receptor agonist. It mimics ghrelin to stimulate the pituitary to release growth hormone. Unlike injectable GH secretagogue peptides, it survives oral administration intact, making it accessible without needles. It has a 24-hour half-life allowing once-daily dosing and is the most extensively human-studied compound in the GH secretagogue category.
They work on the same receptor (GHSR-1a) but have different pharmacokinetic profiles. Ipamorelin is an injectable peptide with a short half-life (~2 hours) that produces sharp, pulsatile GH pulses. MK-677 is an oral small molecule with a 24-hour half-life that produces more sustained GH elevation. Ipamorelin is more selective with fewer side effects; MK-677 is more convenient and more extensively studied in humans.
Yes, substantially. IGF-1 elevation is one of the most consistent findings across MK-677 human trials. At 25 mg/day, IGF-1 increases of 40–80% from baseline have been documented. This IGF-1 elevation is responsible for many of MK-677's anabolic and body composition effects — and also for the insulin resistance concern, since IGF-1 and GH together impair insulin signalling.
Chronic MK-677 use is associated with meaningful increases in fasting glucose and insulin levels in clinical trials. It does not directly cause type 2 diabetes in healthy individuals, but it worsens insulin sensitivity — which is a risk factor for developing diabetes over time with chronic use. Anyone with pre-existing metabolic issues, family history of diabetes, or elevated baseline glucose should be cautious and monitor blood work.
GH and IGF-1 levels rise within days of starting MK-677. Sleep quality improvements (deeper sleep, more vivid dreams) are often noticed within the first week. Body composition changes — increased lean mass, reduced fat — are typically noticeable after 8–12 weeks of consistent use. Water retention appears quickly and may initially mask body composition improvements.
No. MK-677 is a growth hormone secretagogue — it stimulates your own GH production. Anabolic steroids are synthetic hormones that act directly on androgen receptors to promote muscle growth. MK-677 doesn't interact with androgen receptors and won't cause the androgenic side effects (acne, hair loss, hormonal suppression) associated with anabolic steroids.